PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma

Recent results of randomized phase III studies of FDG-PET-adapted therapy for advanced Hodgkin lymphoma (HL) have clearly demonstrated benefit to alteration of treatment according to interim response, in particular regarding reducing toxicity while maintaining efficacy. However, these studies have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Noemie, Crump, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268111/
https://www.ncbi.nlm.nih.gov/pubmed/32537115
http://dx.doi.org/10.1177/2040620720914490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268111/
https://www.ncbi.nlm.nih.gov/pubmed/32537115
http://dx.doi.org/10.1177/2040620720914490

Ejemplares similares